This randomized clinical trial assesses the effect of a single intravenous infusion of bamlanivimab vs placebo on incidence of COVID-19 among residents and staf
The U.K. Locks Down Further as Alarm About Virus Variant Grows
Last Updated
Jan. 4, 2021, 5:18 a.m. ETJan. 4, 2021, 5:18 a.m. ET
Salt Lake City said all schools will reopen after teachers are vaccinated. The U.S. reached a deal with Pfizer on additional vaccine doses. Here’s the latest on the pandemic.
This briefing has ended. Follow our
Here’s what you need to know:
Police officers patrolling London on Monday.Credit.Andrew Testa for The New York Times
Struggling to limit the spread of a potentially more infectious variant of the coronavirus, the British government ordered more sections of England to be placed under the most restrictive lockdown measures on Wednesday, as health officials said severely curtailing human contact was the only way to protect people.
Covid Antibody Drugs Go Unused as Need Soars
While such treatments are promising, their use has been slowed by testing lags, overwhelmed hospitals and a perception the therapies are only for well-connected people.
A box of Eli Lilly’s antibody treatment, bamlanivimab, at Floyd Medical Center in Rome, Ga. Despite worries that the drug would be scarce, the hospital has infused about 100 patients and has not had to turn anyone away.Credit.Floyd Medical Center
Published Dec. 23, 2020Updated Feb. 26, 2021
When federal regulators approved two antibody treatments last month for emergency use in high-risk Covid-19 patients, doctors worried there would not be enough to go around.
Share this article
Share this article
INDIANAPOLIS, Dec. 14, 2020 /PRNewswire/ Eli Lilly and Company (NYSE: LLY) today announced that qualified physicians may now enroll patients in the study New IDEAS: Imaging Dementia Evidence for Amyloid Scanning at New IDEAS-Study.org. New IDEAS builds off the historic IDEAS Study, the largest Alzheimer s disease study ever conducted with over 18,000 participants.
1 The new study will enroll 7,000 participants and investigate the impact of amyloid positron emission tomography (PET) scans on patient management and associated health outcomes in a more diverse population, with a goal of over 50% of study participants identifying as Black/African American or Hispanic/Latino.